Sunphenon in Progressive Forms of Multiple Sclerosis
Launched by FRIEDEMANN PAUL · Nov 28, 2008
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
The hypotheses of our study are:
Sunphenon EGCg has an antiinflammatoric effect due to its impact on the T-cell-proliferation and the inhibition of the activity of NF-Kb.
Sunphenon EGCg has a neuroprotective effect due to its antioxidative potence as a radical scavenger.
A 30 month treatment with Sunphenon EGCg is safe and well-tolerated.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary or secondary chronic progressive multiple sclerosis (ms)
- • EDSS 3-8
- • Age 18-65
- Exclusion Criteria:
- • Relapsing-remitting ms
- • Immunodulatoric or immunosuppressive therapy
- • pretreatment with Mitoxantron, Natalizumab, Rituximab, Azathioprin \<2 month before screening
- • pretreatment with Glairameracetat or beta-Interferons \<4 weeks before screening
- • signs of hepatic dysfunction
- • active ulcus ventriculi or duodeni
- • neoplasias if not cured \>1 year before screening
About Friedemann Paul
Friedemann Paul is a distinguished clinical trial sponsor known for its commitment to advancing innovative therapies in the field of neurology. With a strong emphasis on patient-centered research and rigorous scientific methodology, the organization specializes in developing and conducting clinical trials aimed at understanding and treating neurological disorders. Leveraging a robust network of clinical sites and collaborations with leading research institutions, Friedemann Paul strives to deliver impactful results that enhance patient care and contribute to the broader medical community's understanding of complex neurological conditions. Through its dedication to excellence and ethical research practices, the sponsor is poised to make significant contributions to the advancement of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Patients applied
Trial Officials
Friedemann Paul, Dr.
Principal Investigator
Charite University (NeuroCure Clinical Research Center)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials